| Today | ||||
Conference call to… Story temporarily locked. | ||||
| Over a month ago | ||||
Deutsche Bank analyst… Deutsche Bank analyst George Hill lowered the firm's price target on R1 RCM to $28 from $30 and keeps a Buy rating on the shares. The company announced several new deals and capacity expansion on its Q1 call, "providing the green shoots for 2023 growth," Hill tells investors in a research note. | ||||
Sees GAAP operating… Sees GAAP operating income of $200 million to $220 million; Adjusted EBITDA of $385 million to $405 million | ||||
Reports Q1 revenue… Reports Q1 revenue $385.7M, consensus $384.19M. "Our team remains highly committed to delivering strong results to our customers and the patients they serve, and I am proud of our execution in the first quarter," said Joe Flanagan, president and chief executive officer of R1. "Demand for our solutions remains very robust, and we plan to increase our deployment capacity to support higher market demand and associated growth for R1 in the years ahead. Our pending acquisition of Cloudmed is on track for completion by the end of June and we are excited about the incremental value that we expect the combined company to deliver to our stakeholders." | ||||
R1 RCM and ScionHealth… R1 RCM and ScionHealth have entered into a 10-year agreement that will make R1 the exclusive provider of revenue cycle management - RCM - services for ScionHealth's 61 long-term acute care hospitals - LTACHs -. Launched in December 2021, ScionHealth is a new health system comprised of 61 LTACHs previously owned by Kindred Healthcare and 18 short-term acute care community hospitals previously owned by LifePoint Health. | ||||
Guggenheim analyst Jack… Guggenheim analyst Jack Wallace initiated coverage of R1 RCM with a Neutral rating. The analyst said that R1 RCM is well positioned to benefit from IDNs and other large provider groups seeking to reduce cost and improve revenue capture. Wallace added, however, that the market is pricing in much of the value proposition already, leading him to a Neutral rating. | |
Cloudmed Teach-In will be… Cloudmed Teach-In will be held on April 12 at 12 pm. Webcast Link | |
Cloudmed Teach-In will be… Cloudmed Teach-In will be held on April 12 at 12 pm. Webcast Link | |
R1 RCM announced that… R1 RCM announced that Project Roadrunner Parent Inc., a wholly owned subsidiary of R1, has publicly filed a registration statement on Form S-4 relating to its previously announced proposed acquisition of Cloudmed. R1 and Cloudmed announced their definitive transaction agreement on January 10, 2022. Upon closing of the transaction, current R1 shareholders will own approximately 70% of the combined company on a fully diluted basis and Cloudmed equity holders will own approximately 30%. Cloudmed equity holders will enter into an 18-month lockup agreement, subject to partial early release after six months under certain circumstances. The transaction, which has been unanimously approved by the Board of Directors of R1 and the Board of Managers of Cloudmed, is expected to close in the second quarter, subject to approval of the stock issuance by R1 shareholders, the effectiveness of the aforementioned registration statement on Form S-4, receipt of regulatory approvals and the satisfaction of other customary closing conditions. |
| Over a quarter ago | ||||
Healthcare Analyst… Healthcare Analyst Santangelo, along with Chris Harrison, SVP at Quorum Health, discuss RI RCM and revenue cycle management landscape on an Analyst/Industry conference call to be held on March 4 at 11 am. Webcast Link | ||||
